← Leaderboards
Stephanie Halene
Cincinnati Childrens Hosp Med Ctr
$11,999,602
Attributed
$21,880,083
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.2M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,880,083 · 11
By mechanism
R01$10,993,106 · 5
U54$8,651,289 · 3
U01$8,588,377 · 2
K08$647,311 · 1
Top collaborators
- Rong Fan14 shared
- Ranjit Bindra6 shared
- H Leighton Grimes5 shared
- Diane S. Krause3 shared
- Zongming Ma2 shared
- Mina Luqing Xu2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPhenotypeMolecularInsightProteinsResponseMapsPlaySpecimenBiologicalTechnologyProgramsSamplingCell TypeMutationLeukemiaAffectHematopoiesisImmuneEventAgingSynergismHematologyMotivation
Grant awards (45)
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)$4,112,122
U01 · FY2025 · CA
Yale TMC for Cellular Senescence in Lymphoid Organs$1,300,001
U54 · FY2025 · AG
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$585,107
R01 · FY2025 · CA
Modeling myelodysplasia$578,295
R01 · FY2025 · CA
Core B: Tissue Specimen Core$322,424
U54 · FY2025 · AG · contact PI
Pan-Organ Spatial Atlas of Immunosenescence: Decoding Immune Aging Across Tissues and Scales$300,000
U54 · FY2025 · AG
Yale TMC for Cellular Senescence in Lymphoid Organs$1,299,999
U54 · FY2024 · AG
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)$1,018,682
U01 · FY2024 · CA
Mechanisms of Leukemogenesis in AMKL$657,473
R01 · FY2024 · CA
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$555,851
R01 · FY2024 · CA
Modeling myelodysplasia$554,506
R01 · FY2024 · CA
Core B: Tissue Specimen Core$323,015
U54 · FY2024 · AG · contact PI
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$223,251
R01 · FY2024 · CA
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies$107,220
U01 · FY2024 · CA
Yale TMC for Cellular Senescence in Lymphoid Organs$1,300,000
U54 · FY2023 · AG
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies$1,137,992
U01 · FY2023 · CA
Mechanisms of Leukemogenesis in AMKL$662,414
R01 · FY2023 · CA
Modeling myelodysplasia$577,146
R01 · FY2023 · CA
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$573,404
R01 · FY2023 · CA
Core B: Tissue Specimen Core$324,306
U54 · FY2023 · AG · contact PI
The role of m6A RNA modification as modulator of dsRNA induced cell-intrinsic innate immune responses in hematopoiesis$294,800
R01 · FY2023 · DK · contact PI
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$162,244
R01 · FY2023 · CA
Yale TMC for Cellular Senescence in Lymphoid Organs$1,300,000
U54 · FY2022 · AG
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies$711,873
U01 · FY2022 · CA
Modeling myelodysplasia$592,469
R01 · FY2022 · CA
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML$585,106
R01 · FY2022 · CA
Core B: Tissue Specimen Core$327,140
U54 · FY2022 · AG · contact PI
The role of m6A RNA modification as modulator of dsRNA induced cell-intrinsic innate immune responses in hematopoiesis$294,800
R01 · FY2022 · DK · contact PI
Defining Epigenetic States of Senescent Cells and Associated Tissue Environments in the Human Lymphoid Tissues$200,000
U54 · FY2022 · AG
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies$76,742
U01 · FY2022 · CA
Yale TMC for Cellular Senescence in Lymphoid Organs$1,300,000
U54 · FY2021 · AG
Modeling myelodysplasia$614,181
R01 · FY2021 · CA
Core B: Tissue Specimen Core$354,404
U54 · FY2021 · AG · contact PI
The role of m6A RNA modification as modulator of dsRNA induced cell-intrinsic innate immune responses in hematopoiesis$294,800
R01 · FY2021 · DK · contact PI
Mechanisms of Leukemogenesis in AMKL$1,685,736
R01 · FY2020 · CA
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies$1,423,746
U01 · FY2020 · CA
The role of mutant splicing factor SRSF2 in Myelodysplasia$371,507
R01 · FY2019 · DK · contact PI
The role of mutant splicing factor SRSF2 in Myelodysplasia$371,559
R01 · FY2018 · DK · contact PI
The role of mutant splicing factor SRSF2 in Myelodysplasia$371,610
R01 · FY2017 · DK · contact PI
The role of mutant splicing factor SRSF2 in Myelodysplasia$386,847
R01 · FY2016 · DK · contact PI
Role of C/EBPepsilon in myeloid differentiation$130,861
K08 · FY2010 · DK · contact PI
Role of C/EBPepsilon in myeloid differentiation$130,038
K08 · FY2009 · DK · contact PI
Role of C/EBPepsilon in myeloid differentiation$130,239
K08 · FY2008 · DK · contact PI
Role of C/EBPepsilon in myeloid differentiation$128,463
K08 · FY2007 · DK · contact PI
Role of C/EBPepsilon in myeloid differentiation$127,710
K08 · FY2006 · DK · contact PI